# Jan van de Winkel

Type: Person

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/jan-van-de-winkel
Canonical HTML page: https://getfinancebrief.com/entity/jan-van-de-winkel

## Recent coverage (1 stories)

### Genmab Faces Profit Squeeze as R&D for ADC Pipeline Weighs on 2026 Outlook
2026-02-19 08:27:49 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Genmab A/S reported full-year 2025 revenue of $3.72 billion, missing analyst estimates despite strong growth in its core oncology portfolio. The company is prioritizing long-term growth through its $1.8 billion ProfoundBio acquisition and the global rollout of Epkinly, leading to a temporary contraction in net profit margins.
Full story: https://getfinancebrief.com/story/genmab-q4-2025-earnings-analysis-rd-spending

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.